Diabetic Macular Edema (DME) Active Not Recruiting Phase 3 Trials for Aflibercept (DB08885)

Also known as: Diabetic Macular Edema(DME) / Diabetic Macular Oedema / Macular Edema, Diabetic / Diabetic Macular Edema / Diabetic retinal oedema / Diabetic retinal edema

IndicationStatusPhase
DBCOND0060562 (Diabetic Macular Edema (DME))Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03917472Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaTreatment
NCT02634333Anti-VEGF Treatment for Prevention of PDR/DMEPrevention
NCT03321513DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DMETreatment
NCT03481660A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaTreatment
NCT03481634Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaTreatment
NCT03622580A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)Treatment